Fig. 3.

Role of Nox4 in the context of FLT3-ITD-driven myeloproliferative disease. a Experimental protocol for assessing the impact of Nox4 deletion on steady-state hematopoiesis in Flt3^ITD/wt Mx1-Cre + mice. b WBCs after conditional deletion of Nox4 through 20 weeks. c Spleen weights of Nox4 wt or knockout Flt3^ITD/wt Mx1-Cre + mice. d Immunophenotypic quantification of stem- and progenitor cell abundance, specifically of L⁻K⁺, L⁻S⁺K⁺, HSC (CD48⁻CD150⁺L⁻S⁺K⁺), MPP (CD48⁺CD150⁺L-S⁺K⁺ or CD48⁺CD150⁻L⁻S⁺K⁺ or CD48⁻CD150⁻L⁻S⁺K⁺), GMP (CD34^highFcgR^highL⁻S⁻K⁺), CMP (CD34^highFcgR^lowL⁻S⁻K⁺), and MEP (CD34^lowFcgR^lowL⁻S⁻K⁺). e, f Immunophenotypic quantification of mature myeloid (Gr-1⁺ or Mac1⁺), B-lymphoid (CD19⁺), and T-lymphoid (CD3⁺) cells in e BM and f blood. Error bars indicate the standard deviation. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-tailed t-test)